摘要
目的:观察去甲氧柔红霉素化疗方案治疗急性髓细胞白血病(AML)和急性淋巴细胞白血病(ALL)的疗效及副作用。方法:收集2009年1月-2010年8月我科收治的初治急性髓细胞白血病和急性淋巴细胞白血病25例,按照诱导方案分成急性髓性白血病采用IA方案化疗组,急性淋巴细胞白血病采用VILP方案化疗组。比较两组CR率及化疗毒副作用发生率。结果:IA组及VILP组CR率为(83.33%和85.71%)。两组不良反应发生率类似,IA组骨髓抑制时间较VILP组长。结论:去甲氧柔红霉素联合化疗治疗急性白血病能达到较好的缓解率,骨髓抑制时间较长。
Objective ：To observe the therapeutic and side effects of chemotherapy with Idarubicin on acute myeloid leukaemia（AML） and acute lymphoblastic leu- kaemia （ALL）. Methods：Twenty - fine patients were admitted to our hospital in January 2009 - August 2010. The patients were divided into IA and VILP groups. Their remission rate and toxic - side effects were compared between the two groups. Results ：The CR rate of the two groups was 83.33% and 85.71%. Similar side - effects of chemotherapy occurred in the two groups. The time of bone marrow suppression was longer in [A group than in VILP group. Conclusion： Chemotherapy with Idarubicin has a better remission rate for ALL and a longer bone marrow suppression time.
出处
《医学信息（中旬刊）》
2011年第2期669-670,共2页
Medical Information Operations Sciences Fascicule
